Literature DB >> 29200417

New guidelines from the NCCN for polycythemia vera.

Ruben A Mesa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29200417      PMCID： PMC8148889     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Authors:  Srdan Verstovsek; Alessandro M Vannucchi; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Keita Kirito; Carlos Besses; Masayuki Hino; Beatriz Moiraghi; Carole B Miller; Mario Cazzola; Vittorio Rosti; Igor Blau; Ruben Mesa; Mark M Jones; Huiling Zhen; Jingjin Li; Nathalie Francillard; Dany Habr; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors:  Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal:  Lancet Oncol       Date:  2016-12-02       Impact factor: 41.316
  3 in total
  3 in total

1.  Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study

Authors:  Yahya Büyükaşık; Rıdvan Ali; Mehmet Turgut; Güray Saydam; Akif Selim Yavuz; Ali Ünal; Muhlis Cem Ar; Orhan Ayyıldız; Fevzi Altuntaş; Müfide Okay; Rafiye Çiftçiler; Özgür Meletli; Nur Soyer; Metban Mastanzade; Zeynep Güven; Teoman Soysal; Abdullah Karakuş; Tuğçe Nur Yiğenoğlu; Barış Uçar; Ece Gökçen; Tülin Tuğlular
Journal:  Turk J Haematol       Date:  2020-02-20       Impact factor: 1.831

2.  Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.

Authors:  Alessandro Rambaldi; Alessandra Iurlo; Alessandro M Vannucchi; Richard Noble; Nikolas von Bubnoff; Attilio Guarini; Bruno Martino; Antonio Pezzutto; Giuseppe Carli; Marianna De Muro; Stefania Luciani; Mary Frances McMullin; Nathalie Cambier; Jean-Pierre Marolleau; Ruben A Mesa; Raoul Tibes; Alessandro Pancrazzi; Francesca Gesullo; Paolo Bettica; Sara Manzoni; Silvia Di Tollo
Journal:  Leukemia       Date:  2020-02-11       Impact factor: 11.528

3.  Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.

Authors:  Alessandro Rambaldi; Alessandra Iurlo; Alessandro M Vannucchi; Bruno Martino; Attilio Guarini; Marco Ruggeri; Nikolas von Bubnoff; Marianna De Muro; Mary Frances McMullin; Stefania Luciani; Vincenzo Martinelli; Axel Nogai; Vittorio Rosti; Alessandra Ricco; Paolo Bettica; Sara Manzoni; Silvia Di Tollo
Journal:  Blood Cancer J       Date:  2021-03-06       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.